ATE452129T1 - N-phenyl-2-pyrimidine-amine derivatives - Google Patents

N-phenyl-2-pyrimidine-amine derivatives

Info

Publication number
ATE452129T1
ATE452129T1 AT01984640T AT01984640T ATE452129T1 AT E452129 T1 ATE452129 T1 AT E452129T1 AT 01984640 T AT01984640 T AT 01984640T AT 01984640 T AT01984640 T AT 01984640T AT E452129 T1 ATE452129 T1 AT E452129T1
Authority
AT
Austria
Prior art keywords
pyrimidine
phenyl
amine derivatives
preparation
medicaments
Prior art date
Application number
AT01984640T
Other languages
English (en)
Inventor
Hans Buerger
Giorgio Caravatti
Juerg Zimmermann
Paul Manley
Werner Breitenstein
Margaret Cudd
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9899367&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE452129(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE452129T1 publication Critical patent/ATE452129T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01984640T 2000-09-13 2001-09-11 N-phenyl-2-pyrimidine-amine derivatives ATE452129T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0022438.6A GB0022438D0 (en) 2000-09-13 2000-09-13 Organic Compounds
PCT/EP2001/010503 WO2002022597A1 (en) 2000-09-13 2001-09-11 N-phenyl-2-pyrimidine-amine derivatives

Publications (1)

Publication Number Publication Date
ATE452129T1 true ATE452129T1 (de) 2010-01-15

Family

ID=9899367

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01984640T ATE452129T1 (de) 2000-09-13 2001-09-11 N-phenyl-2-pyrimidine-amine derivatives

Country Status (13)

Country Link
US (3) US7081532B2 (de)
EP (1) EP1322634B1 (de)
JP (1) JP2004509111A (de)
CN (2) CN100406452C (de)
AT (1) ATE452129T1 (de)
AU (1) AU2002218167A1 (de)
BR (1) BR0113838A (de)
CA (2) CA2416274C (de)
DE (1) DE60140814D1 (de)
ES (1) ES2336891T3 (de)
GB (1) GB0022438D0 (de)
PT (1) PT1322634E (de)
WO (1) WO2002022597A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
WO2003000186A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel phenylamino-pyrimidines and uses thereof
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
US7494997B2 (en) 2002-06-28 2009-02-24 Nippon Shinyaku Co., Ltd. Amide derivative
CA2494061C (en) * 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
CA2439440A1 (en) 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
WO2004033446A1 (en) * 2002-10-09 2004-04-22 Danter Wayne R Protein tyrosine kinase inhibitors
AU2003232650A1 (en) * 2003-05-06 2004-11-26 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
WO2004108699A1 (en) * 2003-06-06 2004-12-16 Natco Pharma Limited Process for the preparation of the anti-cancer drug imatinib and its analogues
JP2006527230A (ja) * 2003-06-13 2006-11-30 ノバルティス アクチエンゲゼルシャフト Ｒａｆキナーゼ阻害剤としての２−アミノピリミジン誘導体
MXPA06007237A (es) 2003-12-25 2006-08-18 Nippon Shinyaku Co Ltd Derivado de amida y medicamento que lo contiene.
JPWO2005063720A1 (ja) * 2003-12-25 2007-07-19 日本新薬株式会社 アミド誘導体及び医薬
PE20051096A1 (es) * 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
WO2006017353A2 (en) * 2004-07-13 2006-02-16 GOVERNMENT OF THE UNITED STATES, as represented byTHE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of viral infections
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
EA013328B1 (ru) 2004-09-09 2010-04-30 Натко Фарма Лимитед Производные фениламинопиримидина как ингибиторы bcr-abl
US7939541B2 (en) * 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
CN1939910A (zh) * 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
CN1972917B (zh) * 2004-12-31 2010-08-25 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
JP2008546729A (ja) * 2005-06-23 2008-12-25 ノバルティス アクチエンゲゼルシャフト イマチニブおよび血液脳関門で活性な排出ポンプの阻害剤またはデメチルイマチニブを含む組合せ剤を投与することを含んでなる固形腫瘍疾患の処置法
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
NZ566862A (en) * 2005-09-27 2010-12-24 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of C-kit receptors
US8067421B2 (en) * 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US7977348B2 (en) * 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
MX2009002336A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones de imatinib.
CA2662677C (en) 2006-09-05 2016-05-31 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
KR20090061055A (ko) * 2006-10-26 2009-06-15 시코르, 인크. 결정질 및 비결정질 이매티닙 염기, 이매티닙 메실레이트 및 이들의 제조 방법
EP1988089A1 (de) 2006-10-26 2008-11-05 Sicor, Inc. Imatinib-Base und Imatinib-Mesylat und Herstellungsverfahren dafür
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
KR101122481B1 (ko) * 2007-05-04 2012-02-29 아이알엠 엘엘씨 Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 피리미딘 유도체 및 조성물
US20090012296A1 (en) * 2007-05-29 2009-01-08 Alexandr Jegorov Processes for the preparation of crystalline form beta of imatinib mesylate
CA2689989A1 (en) * 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
BRPI0815572A2 (pt) 2007-08-22 2015-02-18 Irm Llc Compostos e composições como inibidores de quinases
WO2009026276A1 (en) * 2007-08-22 2009-02-26 Irm Llc 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2240175B1 (de) * 2008-02-11 2013-01-02 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Verbindungen mit mdr1-inverser aktivität
MX2010008926A (es) 2008-02-15 2011-02-23 Rigel Pharmaceuticals Inc Compuestos de pirimidin-2-amina y su uso como inhibidores de jak cinasas.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PL2300013T5 (pl) 2008-05-21 2025-04-28 Takeda Pharmaceutical Company Limited Pochodne fosforu jako inhibitor kinazy
KR20160011713A (ko) * 2008-06-27 2016-02-01 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 신경섬유종 및 관련 종양을 억제 및/또는 치료하기 위한 물질 및 방법
WO2010006438A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CN101417995B (zh) * 2008-11-21 2012-06-06 陈依军 苯氧基嘧啶衍生物及其制备方法和用途
EP2419425A4 (de) 2009-04-15 2012-08-29 Astrazeneca Ab Imidazolsubstituierte pyrimidine zur behandlung von glykogensynthasekinase-3-bedingten erkrankungen wie etwa morbus alzheimer
US8816077B2 (en) 2009-04-17 2014-08-26 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
CN102212057B (zh) * 2011-04-13 2013-11-27 合肥工业大学 一种羧酸类非甾体抗炎药衍生物及其制备方法和用途
EP2704572B1 (de) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Verfahren zur hemmung der zellproliferation bei efgr-vermitteltem krebs
CN102796110B (zh) * 2011-05-23 2016-03-30 复旦大学 苯胺嘧啶化合物及其制备方法和用途
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
CN103044394A (zh) * 2012-12-20 2013-04-17 北京理工大学 一种苯基氨基嘧啶衍生物及其制备方法和用途
CN103058935B (zh) * 2013-01-15 2015-05-06 四川大学 一种嘧啶类化合物及其制备方法和用途
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN105859683B (zh) * 2016-04-11 2018-09-28 连云港恒运药业有限公司 伊马替尼的高纯度工业制备工艺
CN107805240A (zh) * 2016-09-08 2018-03-16 中国科学院合肥物质科学研究院 一种新型的pdgfr激酶抑制剂及其用途
CN107652266A (zh) * 2017-10-27 2018-02-02 上海应用技术大学 一种靶向酪氨酸激酶小分子抑制剂及其应用
US20220048893A1 (en) * 2019-03-05 2022-02-17 Hongyi & Associates Llc Compounds for Treating Neurodegenerative Diseases and Cancers
CN110078708B (zh) * 2019-05-08 2020-12-11 东南大学 Smo/Bcr-Abl双靶向抑制剂及其合成方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (de) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
CA2416274C (en) 2011-01-04
US7329661B2 (en) 2008-02-12
DE60140814D1 (de) 2010-01-28
CA2687476A1 (en) 2002-03-21
GB0022438D0 (en) 2000-11-01
BR0113838A (pt) 2003-06-03
PT1322634E (pt) 2010-02-22
US20060223818A1 (en) 2006-10-05
US7312216B2 (en) 2007-12-25
CN1525967A (zh) 2004-09-01
US20040102453A1 (en) 2004-05-27
EP1322634B1 (de) 2009-12-16
US20070265292A1 (en) 2007-11-15
AU2002218167A1 (en) 2002-03-26
US7081532B2 (en) 2006-07-25
HK1057752A1 (en) 2004-04-16
CN100406452C (zh) 2008-07-30
EP1322634A1 (de) 2003-07-02
WO2002022597A1 (en) 2002-03-21
CN1872850A (zh) 2006-12-06
CA2416274A1 (en) 2002-03-21
ES2336891T3 (es) 2010-04-19
JP2004509111A (ja) 2004-03-25

Similar Documents

Publication Publication Date Title
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
SE0101387D0 (sv) Novel compounds
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
TW200510392A (en) Chemical compounds
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
SE9900961D0 (sv) Novel compounds
TW200505452A (en) Chemical compounds
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
ATE233754T1 (de) Diphenyl-piperidin derivate
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE325809T1 (de) Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl- amino-5-phenyl-pentansäure
TW200504051A (en) Novel acridine derivatives and their use as medicaments
DE602004022783D1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
WO2004108094A3 (en) Sulfonamide-substituted chalcone derivatives and their use to treat diseases
ATE315038T1 (de) Antibakterielle mittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1322634

Country of ref document: EP